Career Narrative - University of Wyoming

Transcription

CAREER NARRATIVE
Hermann M. Schätzl, M.D., Professor, Wyoming Excellence Chair
This summary will mainly focus on highlights and major accomplishments at the Technische
Universität München (Technical University of Munich (TUM)), Munich, Germany, from October 2002 to
the current time with some comment on prior employment.
From 2002 to 2010 I was Professor of Clinical Virology (tenured) at the 'Technische Universität
München' (Technical University of Munich, TUM), Munich Germany, one of the leading universities in
Germany and Europe (rank 1 or 2 in Germany, rank 10 or 11 in Europe, ~rank 50 worldwide). In this
position I am head of the Clinical Virology Section at the Institute of Virology of the Technical University
of Munich. For the year 2010 I am on leave at the TUM.
In January 2010 I started my appointment at the University of Wyoming as ‘Wyoming Endowed
Excellence Chair in Prion Biology’. I am currently transferring my laboratory and my research projects
from Munich to Laramie, to establish a fully functional prion laboratory and research group there, with a
new emphasis on CWD-related prion research.
Research (35%)
Prion research
My primary research interest is in the molecular and cellular biology of prion diseases, with a
strong emphasis on experimental therapeutic and prophylactic approaches. This includes study of infectious
neurodegenerative disorders in general, analysis of the cellular and molecular biogenesis and pathogenesis
of prion proteins and prions, establishment of cell culture models for prions and amyloidic proteins,
analysis of the relationship between prions and autophagy, and
study of modifiers of prion
diseases/infections, among others.
Prion diseases are infectious and fatal neurodegenerative disorders of man and animals which are
characterized by spongiform degeneration in the central nervous system. Examples are chronic wasting
disease (CWD) in elk and deer, scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, and
Creutzfeldt-Jakob disease (CJD, vCJD) in humans. The disease is characterized by a rapidly progressing
course that leads inevitably to death, usually within a few months. Typically, this is preceded by a long
incubation time entirely free of symptoms, lasting for years to many decades in humans. Although prion
diseases are usually rare, they have the potential to be transferred within and also between species by
infection processes, giving then raise even to epidemic scenarios. CWD, discovered by the late Beth
Williams, is currently the most infectious prion disease. CWD spreads tremendously and is hardly to
control as wild living animals are also affected.
My prion research started in 1993 as a postdoc at UCSF (1993-1995) with the later nobel prize
laureate (1997) Stanley B. Prusiner. I am internationally recognized for my prion research work as
Career Narrative Hermann M. Schätzl, M.D., Professor
2
evidenced by research awards, invited lectures, and numerous research grants. In the area of cell culture
models for study of prions my laboratory is certainly one of the leading ones. In prion research a major
focus is the evaluation of potential therapeutic and prophylactic anti-prion strategies. This is mainly done in
persistently prion-infected cultured cells, usually followed by in vivo studies in prion-infected animals.
Various cell culture models for study of prion propagation and clearance were established by my group.
We were able to define various novel experimental anti-prion strategies (e.g. drug-induced
intracellular re-routing of PrPc; Gilch et al., EMBO J 2001) and were widening such mechanistic
approaches of interfering with the surface location of PrPc to other classes of compounds (e.g. polyclonal
anti-PrP auto-antibodies (Gilch et al., JBC 2003; Polymenidou et al., PNAS 2004) and anti-PrP
peptide/RNA aptamers (Proske et al., ChemBioChem 2002, Gilch et al., JMB 2007 and CMLS 2009). The
group is also interested in the subcellular trafficking of PrP and prions (Nunziante et al., JBC 2003; Gilch et
al, Traffic 2004; Heiseke et al., Traffic 2008), the cellular clearance of prions (Ertmer et al., JBC 2004 and
Leukemia 2007; Aguib et al., CMN 2008 and Autophagy 2009, Heiseke et al., JNC 2009), modifiers of
prion infections (Bach et al., JBC 2009), and in the molecular and cellular analysis of the species barrier
(Schätzl et al., JMB 1995 and Lancet 1997; Wopfner et al., JMB 1999), including now the zoonotic
potential of CWD.
My previous postdoc Dr. Ina Vorberg has in the meantime established her own research group
which is tightly connected with my group. Ina, a previous postdoc at the NIH in Montana with Dr. Sue
Priola, is an internationally recognized expert in cell culture models for study of prions and has recently
established a rather new area of research: study of model proteins (she mainly uses a yeast prion) for
intracellular aggregation and for study of transmission of aggregates between cells (Krammer et al., FASEB
J 2008, Prion 2008 and 2009, PNAS 2009 (Cover story!)). Ina has recently obtained a professorship at the
newly established 'German Center for Neurodegeneration' in Bonn, Germany and will move there with her
entire group in spring 2010. Our groups will continue to closely collaborate.
Some highlights:
A) Phylogeny of PrPc and species barrier aspects:
Most comprehensive analysis of PrP genes: Our work resulted in sequencing of PrP genes of more
than 50 species (Schätzl et al., JMB 1995 and Wopfner et al., 1999). Both papers are cited about 200 times
and represent milestones in prion research. This comparative analysis of PrPs also provided insights into
variable and conserved regions of PrP and species barrier aspects. We provided also the first description of
the codon 132 polymorphism in deer (Schätzl et al., Lancet 1997).
B) Establishment of cell culture models for primary and persistent prion infection:
ScGT1 cells (Schätzl et al., JV 1997): This is the first cell culture model describing apoptosis and
autophagic cell death as well as exosomal release of prions. To date ScGT1 cells are the most widely used
model for persistent prion infection which also allows propagation of a variety of prion strains. This
3
publication is cited more than 130 times. ScHpl (Maas et al., JBC 2007): This is a knock-out cell line
which can be reconstituted with a PrP of choice becoming then susceptible to prion infection.
C) Cell biology of prion proteins and prions:
Quality control and re-routing and therapeutic implications (Gilch et al., EMBO J. 2001);
Intracellular signalling and implications for PrPc and PrPSc (Spielhaupter & Schätzl, JBC 2001 and Ertmer
et al., JBC 2004). Prion-like propagation of cytosolic protein aggregates (Krammer et al., FASEB J. 2008.
Prion 2008 and 2009; PNAS 2009 (Cover story)).
D) Vaccine development:
We provided the first description of successful auto-vaccination against PrPc using a PrP dimer
(Gilch et al., JBC 2003; Polymenidou et al., PNAS 2004 and Kaiser-Schulz et al., JI 2007). European and
U.S. patents were filed in 2001 and granted.
E) Prion infection and autophagy:
Our work resulted in the first mechanistic description of the role of autophagy in prion infection
(Ertmer et al., JBC 2004 and Leukemia 2007; Aguib et al., Autophagy 2009 and Heiseke et al., JNC
2009).
I was speaker of national and international prion research projects. For example, I was work
package leader of the EU consortium 'Prion Dimers' and within the EU-funded network of excellence
NeuroPrion (EU grant, NoE, 2007-2009).
On a regular basis I was acting as external referee for international research journals and on
scientific boards. From 2002-2008 I was an elected member of the 'Scientific Advisory Board' of the
German TSE platform. I am a member of the MRC New Therapies Scrutiny Group, U.K., national advisor
for BMBF, DFG, and various ministries, and served on international advisory boards (e.g. MAFF,
BBSRC, DH, MRC; U.K.; French, Italian and Austrian research foundations). My ad hoc journal referee
activity included Science, Nature, PNAS, EMBO J., Ann. Neurol., JExpMed, JBC, MCB, JCS, FASEB J.,
FEBS Letters, FEBS J., Gene, Trends Mol. Med., J. Gen. Virol., J. Virology, J. Neurochem., MCN,
Traffic, J. Mol. Biol., PLoS Pathogens; PLoS Medicine, PLoS One, and Prion.
Applied and molecular virology
My second research interest was in applied/diagnostic and molecular virology. Starting as a young
M.D. student working on oncogenic animal retroviruses (SSV/SSAV; v-sis oncogene; Schätzl et al.,
Oncogene 1989), I switched to HIV (protease inhibitors; Schätzl et al., Arch.Virol. 1991; this is one of the
first 2 publications showing that inhibition of HIV-protease might have therapeutic potential!), and STLVI/HTLV-I (Schätzl et al., Leukemia 1992 and 1993; Voevodin et al., JV 1996). Early on there was over
many years a collaboration with groups from the former U.S.S.R. and I was a visiting scientist at the 'All
Union Cancer Research Center' in Moscow and at the 'Primate Research Center Sukhumi/Sochi (the
biggest one in the world) in Sukhumi/Abrasia (now Georgia) before the year 1991. In 1991 I very
4
successfully started to establish a diagnostic PCR laboratory at the Max von Pettenkofer-Institute in
Munich (Ludwig-Maximilians-University of Munich, Germany). At that time by far the most part of
clinical virologists in Germany opposed the idea of using PCR technology for viral diagnosis. In 1992 we
had established PCR test formats for the majority of relevant human viruses (for example, Schätzl et al.,
JMedVirol 1994a and b) and had organised a PCR Diagnostic Unit which was headed by me (with ~5-6
full-time technicians). This was probably the first PCR unit in an academic virology institution in
Germany. From 1991-1992 I was also heading the Hepatitis Virus laboratory at the Max von PettenkoferInstitute and worked on hepatitis viruses (Jilg et al., J.Hepatol. 1995 and Schätzl et al., Hepatology 1995).
On that time I was a nationally and internationally recognized expert in PCR diagnostics and was invited
to present lectures on this topic on many occasions. In these years I also participated in clinical vaccine
studies, mainly dealing with HAV (e.g. Jilg et al., J.Hepatol. 1993). After my postdoc time at UCSF I
returned 1995 to the Max von Pettenkofer-Institute and kept on participating in clinical virology and
diagnostics. I was vice head of the clinical virology unit and of the PCR unit. We transformed at that time
most of the classical PCR test formats into real time PCRs. On a regular basis I was also heading the
diagnostic unit. Besides PCR we also established immunoblot test formats (e.g. Sandfly virus; Schwarz et
al., Res. Virol 1998) which are still in use in diagnostic tests. Overall, many publications have resulted out
of my clinical and epidemiological virology work, representing more than 1/3 of my scientific
publications.
SARS-Co virus
Cell-type specific manipulation of host cells by N and ORF7a proteins of SARS-CoV
In our research, we focus on elucidating molecular mechanisms used by SARS-CoV N and the
accessory ORF7a protein for host cell manipulations. Both proteins are known to play a role in apoptotic
scenarios, although depending on the cell type. Here, significant variations seem to exist with respect to
viral propagation and induced cell destruction, towards a more “attenuated” viral life cycle. We address
these issues by identifying interacting proteins of N or ORF7a by yeast-two-hybrid screens, evaluating the
significance of the protein interactions in different cell models and in the context of cellular SARS-CoV
infection, and deciphering functional consequences during the viral life cycle. This work resulted in 2
publications so far (Diemer et al., JMB 2007 and 2009/book chapter); further manuscripts are in
preparations.
Development of anti-SARS-CoV peptide aptamers
Peptide aptamers have emerged as powerful new tools for molecular medicine. They can
specifically bind to a given target protein and thereby interfere with naturally occurring protein
interactions. The Angiotensn-converting enzyme 2 (ACE2) has been identified as the cellular receptor for
SARS-CoV, and the interaction sites with the viral spike (S) protein are well characterised. Consequently,
we want to select peptide aptamers recognising the binding site of S to ACE2 or vice versa. Our
expectation is that binding of aptamers or derived peptides can interfere with the infection process. On the
5
other hand, structure determination of the interacting peptide moieties can build the fundament for rational
drug design to prevent cellular SARS-CoV infection.
Development of vaccine candidates against SARS-CoV
Using an approach combining recombinant proteins (N) and modified vaccinia virus Ankara
(MVA) as vaccine delivery device we were able to induce significant humoral and cellular immune
responses in animal models (Schulze et al., Vaccine 2008). This collaborative work is still in progress.
Publication Activity
Over 86 original publications in peer-reviewed journals, 19 review articles, 11 book chapters, 1
textbook (Molecular Virology; as editor), and 2 patents were published. There are more than 2.300
citations and the cumulative impact factor is above 420.
Supervision of Students and Scientists
Over 50 bachelor, master, diploma and Ph.D. students, and over 20 post-docs and visiting
scientists were supervised.
Oral presentations
Since 1987 by far more than 100 oral presentations (i.e. invited and selected talks) on national and
international scientific meetings and congresses were made. This includes plenary lectures at all large
international prion congresses since 2002 (invited or selected): 2001: Venice, Italy; 2002: Paris, France;
2003 Munich, Germany; 2004 Paris, France; 2005 Düsseldorf, Germany; 2006 Turin, Italy; 2007
Edinburgh, U.K.; 2008 Madrid, Spain; and 2009, Thessaloniki, Greece. The same is true for the annual
congresses of the German (or European) Society of Virology (GfV), based on invitation or selection by
abstract. In 2008, I was invited key-note speaker at the Japanese national prion conference and in 2009 at
the European Clinical Virology meeting in Istanbul, Turkey.
Awards
In 1990 the 'Curt-Bohnewand' Award of the University of Munich, in 1991 a Thesis Award 'summa
cum laude', in 1992
the 'Henry Kaplan Award' (Modern Trends in Human Leukemia X; Wilsede,
Germany), in 1997 the 1. Prize for scientific presentation at the Research Festival Großhadern, Germany,
and in 2008 the award of the 'Japanese Health Science Foundation' (including keynote speaker at 'Prion
2008 Japan' conference) were awarded.
Personal stipends were a post-doctoral fellowship for UCSF/U.S.A. by the Deutsche
Forschungsgemeinschaft (1993-1994), a stipend by the Ciba Foundation, London, U.K, in 1995, and a
stipend at the 2nd Ann. German American Frontiers of Science Symposium, U.S.A., in 1995.
From 2002-2008 I was elected member of the 'Scientific Advisory Board' of the German TSE
platform, 2003 at the Organising Committee for the International Prion Conference Munich, Germany
2003, 2005 at the Organising Committee for the International Prion Conference Düsseldorf, Germany
6
2005, and 2009 at the Organising Committee for the International Prion Conference Thessaloniki, Greece
2009.
Students of mine obtained in 2008 the 'Manchot-Prize' for Biochemistry, TU Munich (student
Florian Schmidt), and the Prize of the Mayor of the City of Freising' (student Yasmine Aguib for master
thesis).
Funded grants
The overall funding so far is over US $12.000.000 (~8.500.000 Euro). In chronological order, this
started in 1990 with the Curt Bohnewand Award, University of Munich, followed by a grant for postdoctoral studies (USA) of the Deutsche Forschungsgemeinschaft (DFG) (1993-1994), a grant from the
Alexander von Humboldt-Society (1996-1998, SUGAR/GARN program), from the Friedrich-BaurFoundation, LMU Munich, Deutsche Forschungsgemeinschaft (German Research Foundation) covering the
years 1997-2010 (~$2.100.000), a second project funded by DFG (2005-2009), a grant funded by BMBF
(German Ministry of Education and Research) (1997-2000), by the Volkswagen-Foundation, various grants
from the European Union (1998-2001, EU-BIOMED; 1999-2002 EU-FAIR; 2002-2005 EU-Framework V;
2003-2008 EU Framework 6, NoE 'Neuroprion' (network of excellence); 2005-2009 EU Framework 6,
STREP), a DFG-funded Collaborative Research Center of Excellence project (SFB-596, project A8, 20012012. $2.100.000), a second Collaborative Research Center of Excellence project (SFB-596, project B12;
2005-2012; $960.000), and a third Collaborative Research Center of Excellence project (SFB-576; 20042008; $540.000), a project funded by the Bavarian BSE-Network (FORPRION; Bavarian Government;
2001-2000, $675.000), a grant by the BMBF (German Ministry of Education and Research; 2002-2007,
$600.000), the Bayerische Forschungsstiftung (Bavarian State Foundation; SARS-CoV), the BMBF
BioChancePlus program (German Ministry of Education and Research; chip development, 2005-2008,
$570.000), the United States Department of Agriculture U.S.D.A. (2006-2010), the Alberta Prion Research
Institute, Alberta, Canada (2007-2012), the DAAD (German Foreign Exchange Service; 2 student grants), a
President's grant from the Technische Universität München (student grant), and a second project funded by
the Alberta Prion Research Institute, Alberta, Canada (2009-2012).
Most recently, a NIH R15 grant was awarded (2011-2014).
Professional service in diagnostics and clinical virology (35%)
In 2002, I moved as a Professor for Clinical Virology and head of the Clinical Virology Unit to
the Technical University of Munich (TUM). We entirely changed the portfolio and the clinical orientation
of the laboratory and established PCR and real time PCR test formats for almost all relevant human
viruses, with an emphasis on persistent virus infections which are of particular relevance in immunocompromised and immuno-suppressed patients (e.g. in a transplantation situation). Our main premises
were to provide accurate qualitative and -if needed- quantitative test results within very short time out of
any clinical relevant test material and to provide a meaningful interpretation for our clinical colleagues.
7
This included counselling with regard to initiation of antiviral therapy and to monitoring of viral loads
under therapy, including also testing for viral resistance. For the latter we had a BMBF-funded research
project with 2 Munich-based companies for establishing and validating chip-based test formats. Other
areas of clinical research were the role of Epstein-Barr virus (EBV) in top athletes (Hoffmann et al.,
JMedVirol 2010a), molecular epidemiology of noroviruses (Hoffmann et al., JMedVirol 2010b), and the
molecular virology of HIV upon therapeutic vaccination using MVA-nef as vaccine (Hoffmann et al.,
FASEB J 2007).
Importantly, already in 2003 our diagnostic unit underwent accreditation and certification (DIN
EN ISO 15189). Accreditation is more than certification, including continuous improvement with
emphasis on pre- and post-analytical performance. Since 2004 I am a certified referee for accreditation of
virological laboratories, participating in on-site reviews at over 50 occasions in all over Germany and
some European countries (e.g. Austria and Turkey). This means I have ample experience in state-of-the-art
laboratory management and laboratory performance according the rules of accreditation and certification.
Within the German Society for Virology (GfV) I am a member of 2 commissions: 'viral infections during
pregnancy/connatal infections' and 'viral safety/safety of blood'.
Our diagnostic unit at present obtains ~20.000 clinical materials and performs >40.000 test per
year, with roughly one third of it being molecular tests (PCR and real time PCR). Sending in hospitals
were the on-site university hospital "Klinikum rechts der Isar" with about 1.100 beds, the German Heart
Center Munich ("Deutsches Herzzentrum München"), and the Pediatric Hospital Schwabing, all wellknown hospitals in Germany. Our personnel consist of 4 medical doctors, 8 technicians and 2 secretary
persons. Techniques used consist of serological tests (e.g. Elisa and immunoblot), neutralisation,
agglutination and immunofluorescence tests, cell culture for viral isolation, various antigen tests, PCR and
quantitative real time PCR, and various genotypic resistance tests. I myself was heading the research &
development unit which established and validated all our home-made in-house tests. In fact, all but 2 (HIV
and HCV) PCR tests were in-house tests. The laboratory participated on a regular basis at external quality
control trials (twice a year). Routinely, the final test results, including accurate and precise clinicalvirological interpretation, for the most important parameters (e.g. quantitative CMV PCR) were provided
at the same day to clinical colleagues, given that test materials were received before 10 a.m. Quality
parameters such as this were validated and improved on a regular basis. This included also an extensive
internal audit system, the rate of positive test results as wells as query of sending-in colleagues on quality
issues every year (on a written basis). I had the allowance to teach and educate colleagues (for a total
period of 2 years) so that they could pass the specialization for microbiology, virology and infection
hygiene (German "Facharzt-Weiterbildung"). Our counselling of medical colleagues included also vaccine
issues and travel medicine. Our unit organized scientific symposia for our sending-in medical colleagues
for which external speakers with a given expertise from all over Germany were invited.
Teaching (20%)
8
Teaching activity started in 1996. From 1986-1992 I was teaching at the Max von PettenkoferInstitute, University of Munich, Medical Faculty, participating in courses mainly (Practical Courses
"Medical Microbiology for medical students"; Practical Course "Medical Microbiology for pharmaceutical
students", Practical Courses "Medical Microbiology for students of dental medicine", and Practical Courses
"Retrovirology for M.D. and Ph.D. students". From 1994-1995, I was a Clinical Instructor at the
Department of Neurology/University of California Medical School San Francisco, U.S.A. After my return
to Munich, I was teaching from 1995-2002 again at the Max von Pettenkofer-Institute, University of
Munich, and at the Gene Center Munich. This included the Practical Courses "Medical Microbiology for
medical students", Practical Courses "Medical Microbiology for pharmaceutical students", Practical
Courses "Medical Microbiology for students of dental medicine", the main lecture series "Medical
Microbiology, Virology and Immunology", the lecture series "Medical Microbiology for Pharmacists", the
lecture series "Tropical Medicine" (WS 1995 - SS 1997), the lecture series "Recent topics in virology" (WS
1995 - SS 1997), the lecture series "Infection and epidemiology", the lecture series "Molecular aspects of
virus-host interaction", the seminar "Discussion of new virological publications", the Practical Courses
"Molecular biology, cell biology and immunology in viral infection", and the seminar "Advices towards
research work in virology". From 1996-2002 I was official lecturer at the Chemical Department of the
LMU Munich. This included the lecture series "New insights in prion research, for M.D. students and
students of chemistry and biology (with chemical faculty), the seminar "Neurodegenerative Disorders"
(with chemical faculty), and the seminar "Newest literature of prion diseases", for M.D. students and
students of chemistry and biology (with chemical faculty). From 1998-2000, I was member of the Harvard
Tutorials IKI-courses of the medical faculty of the LMU Munich (medical infectiology).
From 2002-2009 I was a member of the medical faculty of the Technische Universität München
(TUM). Related lecture series and practical courses were given then here, integrated in teaching activities
of the Departments and Faculties of Biology, Chemistry and Biochemistry of TUM (e.g. "Virology for
Biologists"; with official tutoring of theses of Diploma, Bachelor and Master students). For medical
students I was involved in the main lecture series "Medical Microbiology", held together with the
colleagues from the Institute of Microbiology. Over all semesters (2002-2009) I was evaluated as best
teacher in this lecture series by the students. For example, in the evaluation for the winter semester 2007 I
got marks 1.2 and 1.3, with 1.0 best and 6.0 worst. A related activity existed for the practical courses
"Medical Microbiology" for M.D. students. For students of Biology, Biochemistry and Molecular
Biotechnology, I was responsible and organiser of the lecture series "Medical and Molecular Virology",
which was part of the curriculum of departments at Garching and Weihenstephan of TUM. I was also
organiser of a related practical course "Medical and Molecular Virology", which was a block course over
3 weeks every semester; for Biology, Biochemistry and Molecular Biotechnology students. This was also
part of the curriculum of the Departments at Garching und Weihenstephan (Chemistry, Biology and
Molecular Biotechnology). In addition, I was a faculty member of IMPRS, the "International Max-Planck
Research School for Molecular Medicine", located at the Max-Planck Institute of Biochemistry in
9
Martinsried near Munich, Germany. This is a new international research school, which attracts the best
students from all-over the world (including U.S.A.) and which gained in the meantime a lot of attention,
competing with the best programs in U.S.A. and U.K. Teaching faculty consists of members from both
Munich universities (LMU and TUM), the Helmholtz Center Munich, and the 3 Max-Planck institutes
located in Munich.
In 2011, a total of more than 80 hours of lecturing was done at UW (Prion Biology, Virology
for Medical Students, Student seminar, Mammalian Pathophysiology).
Training of highly qualified personnel
Over the years, 4 M..D. students (Marco Scelsi, Franziska Wopfner, Georg Weidenhöfer and Ingo
Westner), 9 bachelor students (Bettina Frauscher, Sabine Gilch, Frauke König, Elke Maas, Katja
Gopienko, Heike Anders, Martin Schatte, Tobias Wauer and Ann-Kathrin Felux), 10 master students
(Lukas Martin, Alexandra Lantermann, Florian Schmidt, Ulf Dettmer, Yasmine Aguib, Sabine Gilch,
Yasmina Esterlechner, Katja Gopienko, Julia Hoffmann, and Teresa Schäffler) 15 diploma students
(Claudia Diemer, Markus Kalla, Christian Bach, Renate Schick, Carmen Krammer, Gloria Lutzny,
Veronika Huber, Heidi Söllner, Martina Müller, Martha Schneider, Andreas Heiseke, Marlene PulgarRosa, Beate Hagl, Melanie Eck, and Hanna Wolf), 17 Ph.D. students (Christian Spielhaupter, Max
Nunziante, Alexa Ertmer, Gunnar Schulz, Christopher Bruns, Carmen Krammer, Gloria Lutzny, Claudia
Diemer, Christian Bach, Sabine Gilch, Mauricio Ruiz-Hipp, Yasmine Aguib, Andreas Heiseke, Martha
Schneider, Andrea Grassmann, Julia Hoffmann, and Hanna Wolf) , 15 postdocs (Christine BauerBanaschewski, Stefka Stoyanova, Christian Spielhaupter, Franziska Wopfner (M.D.), Inge von Truchsess,
Sigrid Prebeck (M.D.), Max Nunziante, Ina Vorberg, Dieter Hoffmann (M.D.), Alexa Ertmer, Lars
Gädtke, Claudia Diemer, Selma El Bied (M.D.), Sabine Gilch, and Carmen Krammer, and 9 visiting
scientists (Dr. Merabi Chikobava (Russia), Maria Oboznaya (Russia), Xingsheng Hu (China), Dr. Kensuke
Ishikawa (Japan), Evgenia Salta (Greece), Dr. Ivana Hafner-Bratkovic (Slovenia), N.N. (Sweden), Dr. G.
Hajj (Brazil), and Prof. Katsumi Doh-Ura (Japan), and 12 technicians (research only) (Emilia Sieger,
Margret Brand, Helga Mairhofer, Sabine Gilch, Elke Maas, Judith Seebach, Claude Kehler, Romina Rost,
Christiane Baierl, Madlen Ruthenbeck, Kim Dietrich, and Kerstin Ackermann) were supervised or trained.
In 2011, a total of 13 graduate students are supervised (5 as direct advisor, 8 in committee).
Administrative work/university service (5%)
Our unit was itself in charge of almost all administrative, personnel and monetary issues for all our
grants. As head of the unit I had a persistent and very close collaboration and communication with our
administrative personnel in the secretary. Besides scientific reports I was responsible for the technical
reports. In Germany we have a whole variety of regulations with regard to genetic engineering laws and
biosafety issues for which I was the responsible person. In 2008, I was appointed as head of the biosafety
office ("Stabsstelle Biologische Sicherheit") at our hospital. Other administrative work concerned the
10
medical faculty, including regular meetings, education of young colleagues according the German
"Habilitation", and participation at search committees for faculty candidates. Work in the 2 commissions
of the German Society for Virology (GfV) and the various referee activities were mentioned already
above.
In 2011, I successfully headed a search committee (Professor of Immunology; filled) and I am
a member of the search committee “Department Chair” (ongoing).
Public service/media contacts (5%)
Early on there was ample opportunity for exchange with mass media on various topics. On a
frequent basis I was interviewed by journalists from newspapers and journals, broadcasting stations and
TV stations. In the last years I was a national expert for prion diseases, viral diseases including influenza,
and vaccine affairs. In the time period of 1987-1990, theses were mainly talks for layman audiences and
some newspaper reports, covering topics like oncogenesis/cancer, retroviruses and HIV. From 1990-1992
newspaper reports and interviews in newspapers followed, covering main topics like Influenza A/flu, viral
diagnostics, and hepatitis viruses. From 1996-2009 newspapers, Internet, broadcasting and TV activities
followed, with main topics prions, flu and vaccines. Overall topics therefore included oncogenesis, viral
diseases in general, infectious hepatitis, HIV/AIDS, BSE and CJD (prion diseases), Influenza A, avian flu
and swine flu. norovirus, and vaccines in general. Media covered were our German main newspapers (e.g.
Süddeutsche Zeitung, Münchner Merkur, Focus, Spiegel), our main local broadcasting stations (e.g. BR2,
BR1 (Bavarian Broadcasting), Antenne Bayern), Internet-TV (e.g. bild.de internet, Focus.de,
vitanet.docmed.tv, netdoctor.de) and main TV stations (e.g. BR3, Sat1, Pro7, ZDF, WDR (including also
life talk shows, newscast and telecast formats (e.g. welt-der-wunder, faszination wissen, w-wie-wissen).

Career Narrative - University of Wyoming

Transcription

Similar documents

CURRICULUM VITAE Prof. Dr. Hartmut Hengel Albert

as a PDF

Fall 2014 – Honor Roll Class of 2015 High Honors